Research Article

INVESTIGATION OF LIPID LOWERING ACTIVITY OF GSK-3 INHIBITOR

*Manish M. Patel, [1]Kirankumar K. Shah

* Lecturer, Department of Pharmacology, B. S. Patel Pharmacy College, Linch, Mehsana, North Guj., India.
1 Add. Director, Directorate of Medical Education and Research, Gandhinagar. (Gujarat State), India.
*Corresponding author's E-mail: manishh00784@yahoo.co.in

ABSTRACT

Cardiovascular diseases are the number one killer in the united state as well as developed western countries. According to estimates from the American Heart Association, about 80 millions of American people have one or more types of CVD. This is the condition despite of presence of many anti atherosclerotic drugs from long time. That's why we have to move for other option that can cure the atherosclerosis. For that we opted for GSK-3 due to its role in inflammation apoptosis and lipid homeostasis. For this purpose model of advance atherosclerosis was developed and study was conducted on that rat model. Symptoms do not occur until a loss of at least 75% of the vessel diameter, most patients not presenting with less than 90% occlusions. We have used atorvastatin as standard along with ezetimibe for combination therapy while for test drug valproate was used due to its GSK-3 inhibiting activity. Valproate was not as effective as atorvastatin in controlling lipid profile. From biochemical indices analysis it is reasonably to conclude that we have to develop GSK-3 inhibitor which has higher lipid lowering capacity along with anti-inflammatory activity.

Keywords: Atherosclerosis, Vascular injury, High fat fed.

INTRODUCTION

Atherosclerosis is a condition affecting large and medium-sized arteries. It is characterized by the accumulation of various substances like lipids, inflammatory cells, smooth muscle cells and extra-cellular matrix in the sub endothelial space[1]. It is the leading cause of death and disability in the developed world. CVD claims more lives in the US each year than the next five leading causes of death combined [2,3].

Blood pressure, plasma cholesterol and obesity are established cardiovascular risk factors, while plasma levels of interleukin-6 (IL-6), tumour necrosis factor-α (TNF- α), C-reactive protein (CRP), and leptin have also been implicated in atherogenesis [4]. Although blood total cholesterol and low-density lipoprotein cholesterol (LDL-C) are the most frequent lipid components reported in clinical and epidemiological studies, little attention has been paid to levels of high-density lipoprotein cholesterol (HDL-C) and triglycerides. A recent systematic review showed epidemiological evidence of an inverse association between HDL-C levels and stroke risk [5]. Hyperlipidemia and hyperglycemia trigger endothelial generation of reactive oxidant species, activating nuclear transcription factors (NFkB) which induce genes involved in atherosclerosis such as VCAM-1 and MCP-1 [6].

Several pharmaceutical therapies have been developed traditionally to inhibit cholesterol synthesis. These agents, collectively referred to as statins, inhibit the enzyme 3-hydroxymethyl-glutaryl coenzyme A reductase to effectively reduce blood cholesterol levels and represent the standard of care for treatment of dyslipidemia. A new class of cholesterol-lowering therapeutics, called 2-azetidinones, decreases plasma cholesterol levels by blocking intestinal absorption of cholesterol[7]. Co administration of statins and ezetimibe produces dual-pathway inhibition resulting in an additive effect on plasma cholesterol reduction [8]. This therapeutic strategy is particularly effective because the two drug classes decrease cholesterol by distinct mechanisms, inhibition of cholesterol synthesis (statins), and inhibition of cholesterol absorption (ezetimibe). Reduced plasma cholesterol in dogs was found due to either an additive or synergistic manner, depending on the statin employed [9].

The effectiveness of plasma lipid lowering in the clinic is well supported by a growing number of contributions, indicating the significant improvement in cardiovascular risk in primary and particularly in secondary prevention. While these studies have clearly indicated that the more potent agents for cholesterol reduction can provide a very effective help, other pathways of lipid metabolism have gained interest. But these agents give only symptomatic relief. So newer molecular target should be found by which we can treat the atherosclerosis in place of giving symptomatic relief by targeting lipid level as well as inflammation.

Up regulation of Sterol regulatory element binding protein (SREBP) that control lipid biosynthesis and uptake, Capsase-3 which is found in apoptosis and NF-kB that contribute in atherosclerosis associated inflammation is done by GSK-3 [10]. Hence GSK-3 inhibitors may be potential target for prevention of atherosclerosis. In this research we have tried to find out effectiveness of valproate, a potent GSK-3 inhibitor, in combination with ezetimibe. Combination of atorvastatin and ezetimibe was used as a standard treatment. Atorvastatin was selected because of its pleiotropic effect as a GSK-3 inhibitor.

MATERIALS AND METHODS

ANIMALS

Male *Sprague Dawley* rats of weighing 280-350 gm were procured from central animal facility of B. S. Patel Pharmacy College. The care and the use of these animals were in accordance with the guidelines of the CPCSEA. Experimental protocol was approved by Institutional Animal Ethic Committee (IAEC). The rats were divided into 6 groups.

Surgical procedure for femoral artery injury [11]

The rats were anesthetized using ketamine (55 mg/kg, i.m) and diazepam (5 mg/kg, i.m) after shaving of lower ventral region 1.5 cm incision was made adjacent to femoral vessel. The femoral artery was separated carefully from the surrounding fascia and femoral vein and nerve using small curved micro forceps. When the femoral artery was isolated, it was clamped with the help of bull dog. The arteriotomy was performed in the isolated portion of the artery with the metal wire, whose surface was rough and the tip was made blunt and smooth. After making small hole in the wall of the artery metal wire was inserted into the lumen of the femoral artery at a fixed distance. And then it was rotated completely for 3 times and removed carefully. The metal wire was then withdrawn, and after allowing back bleeding through the arteriotomy site, the femoral artery was ligated proximal to the arteriotomy site using 4-0 silk sutures. Then the ligature was tied below the hole in the femoral artery. Thereafter slowly remove the bulldog clamps from the femoral artery. After visual inspection (to ensure adequate pulsation of the femoral artery), the surgical incision was closed, and the rats were allowed to recover from anesthesia. The incisions were closed with the help of the suturing needle. And antiseptic cream was applied on that day.

ANTI-ATHEROSCLEROTIC ACTIVITY PROTOCOL

Glycogen Estimation from Liver [12]: From liver 60 percent potassium hydroxide at 100° C can extract glycogen, that is quantitatively precipitated from a 70 per cent of alcohol, and that the optimal condition for its conversion to glucose is in 2.2 per cent hydrochloric acid at 100° C. Following the conversion of glycogen to glucose, the Glucose can be estimated with the help of titration method. Then concentration of Glucose was converted into Glycogen percentage.

Blood sampling and Serum separation: Un-haemolysed sample of blood was collected from the clean tail tips in eppendroff tubes from the anaesthetized animals. The blood was allowed to clot at room temperature (37°C) and centrifuged at 2500 rpm for 10 minutes at room temperature to separate the serum and subjected to biochemical estimation.

Protocol for Lipid Profile Study:

Estimation of serum Total cholesterol, Triglyceride, and HDL-cholesterol were done by using Standard kit (Nicholas India Pvt. Ltd.) with semi-auto analyzer.

Estimation of TC [13]: Cholesterol esterase (CHE) hydrolyses cholesterol ester. Free cholesterol is oxidized by the cholesterol oxidize (CHO) to choloest-4-ene-3-one and hydrogen peroxide. Hydrogen peroxide reacts with 4-aminoantipyrine and phenol in the presence of peroxidase (POD) to produce pink colored quinoneimine dye. The intensity of color produced is proportional to cholesterol concentration.

Estimation of TG [14]: Triglycerides in the sample are hydrolyzed by microbial lipase to glycerol and free fatty acid (FFA). Glycerol is phosphorylated by adenosine 5-triphosphate (ATP) to glycerol 3-phosphate (G-3-P) in reaction catalyzed by glycerol kinase. G-3-P is oxidized to dihydroxy acetone phosphate in a reaction catalyzed by the enzyme glycerol phosphate oxidase (GPO). In this reaction hydrogen peroxide (H_2O_2) is produced in equimolar concentration to the level of triglycerides present in the sample. H_2O_2 reacts with 4-aminoantipyrine and ADPS in the reaction catalyzed by peroxidases (POD). The result of this oxidative coupling is a quinoneimine purple colored dye. The absorbance of this dye in solution is proportional to the concentration of triglycerides in sample.

Estimation of HDL-Cholesterol[15]: The VLDL and LDL fractions of serum sample are precipitated using PTA and then HDL in the supernatant is separated by centrifugation and measured for its cholesterol content. The enzyme cholesterol ester hydrolase (CHE) hydrolyses the ester cholesterol. Then cholesterol is oxidized by cholesterol oxidase (CHO) to cholest-4-en-3-one and hydrogen peroxide. Hydrogen peroxide in presence of enzyme peroxidase (POD) reacts with 4-aminoantipyrine and phenol to produce a red colored complex, whose absorbance is proportional to HDL-cholesterol concentration.

Estimation of LDL-Cholesterol: Estimation of LDL-cholesterol was done using the Friedewald formula [16].

LDL cholesterol = TC – (HDL-C + VLDL-C)

Estimation of VLDL-Cholesterol: Estimation of VLDL-cholesterol was done using the Friedewald formula [16].

VLDL cholesterol = Triglycerides / 5

Estimation of Atherosclerotic Index: Estimation of Atherosclerotic Index was done by using following formula

Atherosclerotic Index= (Total Cholesterol-HDL)/HDL

Estimation of HDL LDL ratio.

Statistical analysis:

The results were expressed as mean $\pm$ s.e.m., where n represents the number of rats. Statistical difference between two means determined by ANOVA followed by Dunnett post test.

RESULTS:

D Serum HDL

E Serum VLDL

F Serum LDL

Effect of Drug treatment on (A) liver glycogen content, (B) Total Cholesterol content, (C) Triglyceride content, (D) HDL content, (E) VLDL content (F) LDL content, (G) HDL LDL ratio and (H) Atherosclerotic Index in Normal Control, Sham Control with HFF, HFF and injury induced Disease Control, Disease Cont. - AT. (Atorvastatin), Disease Cont.-EZE. (Ezetimibe), Disease Cont.-VAL. (Valproate), Disease Cont.-EZE.– AT., Disease Cont-EZE.-VAL. treated rats. Values are expressed in Mean ± s.e.m. n=4-6. For 0ne way ANOVA followed by Dunnett post test *P < 0.05, **P < 0.01, ***P < 0.001 Vs Disease Control Group.

DISCUSSION

The prime objective of this research project was to postulate the crucial molecular events linking hyperlipidemia and vascular dysfunction associated with atherosclerosis with main emphasis on Glycogen Synthase Kinase- 3 (GSK-3). We have designed our research project to find out newer approach that can cure vascular dysfunction besides only treating elevated blood lipid level by targeting offending molecular target. This type of research is needed because no one perfect drug is available which fits in this role till now. According to World Health Organization in 1999, cardiovascular

disease contributed to one third of all deaths, with 78 % of those deaths occurring in low and middle income countries. This is the status of mortality due to atherosclerosis though we have potent drugs like statins, since more than four decades, which block cholesterol biosynthesis and lowering down blood lipid profile. There are other drugs as well but no one drug gives preventive therapy. We can cure vascular dysfunction by using combination of newly found drug along with conventional lipid lowering agent to mitigate the mortality issue related to the atherosclerosis. Since intima-media thickness (IMT) is a marker for early atherosclerosis

strongly associated with stroke [17] and that can be measured by ultrasound analysis, it is possible to think for preventive drug therapy as well in advance in early stage of the atherosclerosis. By considering all these facts we have made attempt for both the preventive and curative therapy for newer drug and conventional drugs. We have design our research work to the get the idea of effectiveness of combination therapy also.

Glycogen synthase is a rate-controlling step in insulin-stimulated muscle glycogen synthesis so glycogen measurement was performed to elucidate role of GSK-3 in hyperlipidemia state [18]. Decreased glycogen content in atherosclerotic rat liver indicates decreased glycogen synthase (GS) activity and increased activity of Glycogen Synthase Kinase as compare to normal animals. Treatment of atorvastatin ($P < 0.01$) and valproate ($P < 0.01$) in monotherapy and in combination with ezetimibe ($P < 0.001$) shows significant different from disease control animal both in curative and preventive therapy as compare to disease control (fig A). This shows effect of atorvastatin and valproate as a GSK-3 inhibitor and they may be newer drug for prevention of atherosclerosis.

Hypercholesterolemia is one of the most important risk factors for atherosclerosis and coronary heart disease (CHD). Plasma total cholesterol distributes among three major lipoprotein classes including low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), and high-density lipoprotein (HDL). Risk of CHD is positively correlated with LDL cholesterol (LDL-C), whereas it is inversely associated with cholesterol of HDL (HDL-C) [19]. From that LDL is the prime lipoprotein for consideration because it pays main role in atherosclerosis. Oxidized low-density lipoprotein (ox-LDL) causes endothelial dysfunction. Both simvastatin and lovastatin upregulated eNOS expression and completely prevented its downregulation by ox-LDL [20]. A decrease in the catabolism of VLDL triglycerides, chylomicron accumulation in the plasma due to impaired clearance could also be a contributing factor to the increased concentration of triglyceride. Lipolytic products of triglyceride-rich lipoproteins, such as free fatty acids (FFAs), have also been shown to increase the permeability of endothelial monolayers, enhance lipid accumulation in SMCs, promote endothelial production of inflammatory mediators (NF-&B, IL-8, ICAM-1), and alter the extracellular matrix synthesis in cultured SMCs. Studies with both endothelial cells [21] and SMCs [22] have demonstrated that increased fatty acids also increased oxidative stress and can increase NF-&B activation and the expression of NF-AB mediated genes including VCAM-1. Atherosclerotic control animals showed increase in serum triglyceride, total cholesterol, LDL and VLDL while decrease HDL level, compare to normal control rats, indicates abnormalities in lipid metabolism. Atorvastatin inhibits the enzyme 3-hydroxymethyl-glutaryl coenzyme A reductase to reduce blood cholesterol levels effectively with its pleotropic effect on oxidative stress and inflammation and represent the standard for treatment

of dyslipidemia and inflammation associated vascular dysfunction. Ezetimibe, the first-in-class representative of the 2-azetidinones, blocks both dietary and biliary cholesterol absorption in the proximal jejunum in hamsters [7]. In our study Atorvastatin alone and in the combination with the Ezetimibe shows significant decrease in serum triglyceride ($P < 0.001$), total cholesterol ($P < 0.001$), LDL ($P < 0.001$), VLDL ($P < 0.001$) and atherosclerotic index VLDL ($P < 0.001$) while increase in HDL ($P < 0.01$) level and HDL LDL ratio both in curative and preventive therapy. Effect in preventive therapy is higher than curative therapy. While this type of effect for Ezetimibe we found in preventive therapy ($P < 0.01$). No significant hypolipidemic effect was found in the case of valproate treated animal (fig. B-H).

It is reasonably to conclude that, GSK-3 inhibitors has limited role as a hypolipidemic agent. So we have to develop newer analogue of statins that has higher GSK-3 inhibitory activity along with lipid lowering activity.

REFERENCES

1. Fuster V, Corti R, Badimon JJ, The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium--clinical frontiers in atherosclerosis research, *Circ J.*, 66(9), 2002, 783-790.

2. Hoyert DL et al, *Deaths: final data for 2003*, Natl Vital Stat Rep, 54(13), 2006, 1-120.

3. Arias E, United States life tables 2003, *Natl Vital Stat Rep*, 54(14), 2006, 1-40.

4. Woods A, Brull DJ, Humphries SE, Montgomery HE, Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6, *Eur Heart J.*, 21, 2000, 1574-1583.

5. Amarenco P, Labreuche J, Touboul PJ, High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review, *Atherosclerosis*, 196, 2008, 489-496.

6. http://www.a-s-t.org/abstracts98/151.htm

7. Salisbury BG, Davis HR, Burrieer RE *et al,* Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH48461, *Atherosclerosis*, 115, 1995, 45–63.

8. Melani L, Mills R, Hassman D *et al,* Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial, *Eur Heart J.*, 24, 2003, 717-728.

9. Davis Jr HR, Pula KK, Alton KB *et al,* The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs, *Metabolism*, 50, 2001, 1234-1241.

10. Robertson LA, Kim AJ, Werstuck GH, Mechanism linking diabetes mellitus to the development of atherosclerosis: a role for endoplasmic reticulum stress and glycogen synthase kinase-3, *Can J. Physiol. Pharmacol.*, 84, 2006, 39-48.

11. Merce R, John TF, Juan JB et al, Mouse Model of Femoral Artery Denudation Injury Associated With the Rapid Accumulation of Adhesion Molecules on the Luminal Surface and Recruitment of Neutrophils. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 335-347.

12. Osterberg AE, The estimation of glycogen in small amounts of tissue. The journal of biological chemistry, 1929, LXXXV, 97-108.

13. Trinder P, Estimation of serum total cholesterol by using chod-pod enzymatic reaction, Ann. Clin. Biochem, 1969, 6, 24.

14. Cole TG, Kiotzch SG, Mcnamara J, Measurement of triglyceride concentration. In: Rifai N, Warnick Gr, Dominiczak Mh, eds. Handbook of lipoprotein testing, Washington: AACC press, 1997, 115-126.

15. Burstein M et al, Estimation of high density lipoprotein cholesterol in animal by chod-pod reaction, J. Lipid Res., 1970, 11, 583.

16. Friedewald WT, Assay of LDL cholesterol in animal by using formula, Clin. Chem 1972, 18, 499.

17. Hokanson JE, Austi MA, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies, *J Cardiovasc Risk,* 3, 1996, 213-219.

18. Cline GW, Johnson K, Regittnig W *et al,* Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats, Diabetes, 51, 2002, 2903-2910.

19. Austin MA, King MC, Vranizan KM, Krauss RM, Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk, *Circulation*, 82, 1990, 495-506.

20. Laufs U, La Fata V, Plutzky J, Liao KL, Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors, *Circulation,* 97, 1998, 1129-1135.

21. Inoguchi T *et al,* High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C dependent activation of NAD(P)H oxidase in cultured vascular cells, *Diabetes,* 49(11), 2000, 1939-1945.

22. Steinberg HO *et al,* Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production, *Diabetes*, 49(7), 2000, 1231-1238.

About Corresponding Author: Dr. Manish M. Patel

Dr. Manish M. Patel is post graduated from SKPCPER, Ganpat University. He got doctorate degree from Hemchandracharya North Gujarat University. His area of interest is Vascular dysfunction associated mortality. He is working on role of kinase inhibitor in treatment of vascular dysfunction since last 4 years.